Biomarkers in prostate cancer surveillance and screening: Past, present, and future

Therapeutic Advances in Urology

Volumn 5, Issue 6, 2013, Pages 318-329

  Cary, K Clint ^a   Cooperberg, Mathew R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biomarkers; cancer screening; prostate cancer

Indexed keywords

PROENZYME PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN SPECIFICITY; CANCER EPIDEMIOLOGY; CANCER SCREENING; GENE; HUMAN; PCA3 GENE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW;

EID: 84887784853     PISSN: 17562872     EISSN: 17562880     Source Type: Journal    
DOI: 10.1177/1756287213495915     Document Type: Review

References (109)

1. Abdollah F. Sun M. Thuret R. Jeldres C. Tian Z. Briganti A. (2011) A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988–2006. Eur Urol 59: 88–95.
2. Andriole G. Crawford E. Grubb R. Buys S. Chia D. Church T. (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360: 1310–1319.
3. Ankerst D. Groskopf J. Day J. Blase A. Rittenhouse H. Pollock B. (2008) Predicting prostate cancer risk through incorporation of prostate cancer gene 3. J Urol 180: 1303–1308.
4. Antenor J. Han M. Roehl K. Nadler R. Catalona W. (2004) Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study. J Urol 172: 90–93.
5. Aubin S. Reid J. Sarno M. Blase A. Aussie J. Rittenhouse H. (2010) PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial. J Urol 184: 1947–1952.
6. Becker C. Piironen T. Pettersson K. Björk T. Wojno K. Oesterling J. (2000) Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum. J Urol 163: 311–316.
7. Benchikh A. Savage C. Cronin A. Salama G. Villers A. Lilja H. (2010) A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France. BMC Cancer 10: 635.
8. Brawley O. (2012) Trends in prostate cancer in the United States. J Natl Cancer Inst Monogr 2012: 152–156.
9. Bussemakers M. van Bokhoven A. Verhaegh G. Smit F. Karthaus H. Schalken J. (1999) DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 59: 5975–5979.
10. Catalona W. Partin A. Slawin K. Brawer M. Flanigan R. Patel A. (1998) Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279: 1542–1547.
11. Catalona W. Smith D. Ornstein D. (1997) Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 277: 1452–1455.
12. Catalona W. Smith D. Ratliff T. Dodds K. Coplen D. Yuan J. (1991) Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324: 1156–1161.
13. Chan T. Mikolajczyk S. Lecksell K. Shue M. Rittenhouse H. Partin A. W. (2003) Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen. Urology 62: 177–181.
14. Christensson A. Björk T. Nilsson O. Dahlén U. Matikainen M. Cockett A. (1993) Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol 150: 100–105.
15. Christensson A. Laurell C. Lilja H. (1990) Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 194: 755–763.
16. Cooperberg M. Broering J. Carroll P. (2009) Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst 101: 878–887.
17. Cooperberg M. Broering J. Kantoff P. Carroll P. (2007) Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol: S14–S19.
18. Cooperberg M. Lubeck D. Meng M. Mehta S. Carroll P. (2004) The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 22: 2141–2149.
19. Cooperberg M. Pasta D. Elkin E. Litwin M. Latini D. Du Chane J. (2005) The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 173: 1938–1942.
20. Cooperberg M. Simko J. Cowan J. Reid J. Djalilvand A. Bhatnagar S. (2013) Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol 31: 1428–1434.
21. Crawford E. Rove K. Trabulsi E. Qian J. Drewnowska K. Kaminetsky J. (2012) Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases. J Urol 188: 1726–1731.
22. Cuzick J. Berney D. Fisher G. Mesher D. Møller H. Reid J. (2012) Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer 106: 1095–1099.
23. D–Amico A. (2003) Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 21: 2163–2172.
24. D–Amico A. Whittington R. Malkowicz S. Schultz D. Blank K. Broderick G. (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280: 969–974.
25. Darson M. Pacelli A. Roche P. Rittenhouse H. Wolfert R. Saeid M. (1999) Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. Urology 53: 939–944.
26. Deras I. Aubin S. Blase A. Day J. Koo S. Partin A. (2008) PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 179: 1587–1592.
27. Djavan B. Remzi M. Schulman C. Marberger M. Zlotta A. (2002) Repeat prostate biopsy: who, how and when? A review. Eur Urol 42: 93–103.
28. Djavan B. Zlotta A. Kratzik C. Remzi M. Seitz C. Schulman C. (1999) PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL. Urology 54: 517–522.
29. Djavan B. Zlotta A. Remzi M. Ghawidel K. Basharkhah A. Schulman C. (2000) Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. J Urol 163: 1144–1149.
30. Etzioni R. Gulati R. Tsodikov A. Wever E. Penson D. Heijnsdijk E. (2012) The prostate cancer conundrum revisited. Cancer 118: 5955–5963.
31. Etzioni R. Tsodikov A. Mariotto A. Szabo A. Falcon S. Wegelin J. (2007) Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control 19: 175–181.
32. Fang J. Metter E. Landis P. Chan D. Morrell C. Carter H. (2001) Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology 58: 411–416.
33. Finlay J. Evans C. Day J. Payne J. Mikolajczyk S. Millar L. (1998) Development of monoclonal antibodies specific for human glandular kallikrein (hK2): development of a dual antibody immunoassay for hK2 with negligible prostate-specific antigen cross-reactivity. Urology 51: 804–809.
34. Fleshner N. Lawrentschuk N. (2009) Risk of developing prostate cancer in the future: overview of prognostic biomarkers. Urology 73(Suppl.): S21–S27.
35. Gopalan A. Leversha M. Satagopan J. Zhou Q. Al-Ahmadie H. Fine S. (2009) TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 69: 1400–1406.
36. Greene K. Albertsen P. Babaian R. Carter H. Gann P. Han M. (2013) Prostate specific antigen best practice statement: 2009 update. J Urol 189(Suppl.): S2–S11.
37. Groskopf J. Aubin S. Deras I. Blase A. Bodrug S. Clark C. (2006) APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 52: 1089–1095.
38. Guazzoni G. Nava L. Lazzeri M. Scattoni V. Lughezzani G. Maccagnano C. (2011) Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. Eur Urol 60: 214–222.
39. Gudmundsson J. Besenbacher S. Sulem P. Gudbjartsson D. Olafsson I. Arinbjarnarson S. (2010) Genetic correction of PSA values using sequence variants associated with PSA levels. Sci Transl Med 2: 62ra92.
40. Haese A. de la Taille A. Van Poppel H. (2008) Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 54: 1081–1088.
41. Helfand B. Kan D. Modi P. Catalona W. (2011) Prostate cancer risk alleles significantly improve disease detection and are associated with aggressive features in patients with a ‘normal– prostate specific antigen and digital rectal examination. Prostate 71: 394–402.
42. Helfand B. Loeb S. Kan D. Catalona W. (2010) Number of prostate cancer risk alleles may identify possibly ‘insignificant– disease. BJU Int 106: 1602–1606.
43. Hemminki K. Ji J. Försti A. Sundquist J. Lenner P. (2008) Concordance of survival in family members with prostate cancer. J Clin Oncol 26: 1705–1709.
44. Hessels D. Klein Gunnewiek J. van Oort I. Karthaus H. van Leenders G. van Balken B. (2003) DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 44: 8–16.
45. Hessels D. Smit F. Verhaegh G. Witjes J. Cornel E. Schalken J. (2007) Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 13: 5103–5108.
46. Hoque M. (2005) Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol 23: 6569–6575.
47. Houlgatte A. Vincendeau S. Desfemmes F. Ramirez J. Benoist N. Bensalah K. (2012) Use of [-2] pro PSA and phi index for early detection of prostate cancer: a prospective of 452 patients. Prog Urol 22: 279–283.
48. Jerónimo C. Usadel H. Henrique R. Silva C. Oliveira J. Lopes C. (2002) Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology 60: 1131–1135.
49. Kattan M. Eastham J. Stapleton A. Wheeler T. Scardino P. (1998) A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90: 766–771.
50. Khan M. Sokoll L. Chan D. Mangold L. Mohr P. Mikolajczyk S. (2004) Clinical utility of proPSA and ‘benign– PSA when percent free PSA is less than 15%. Urology 64: 1160–1164.
51. Klein E. Maddala T. Millward C. Cherbavaz D. Falzarano S. Knezevic D. (2012) Development of a needle biopsy-based genomic test to improve discrimination of clinically aggressive from indolent prostate cancer. ASCO Meeting Abstracts. J Clin Oncol 30(Suppl.): 4560.
52. Kranse R. Roobol M. Schröder F. (2008) A graphical device to represent the outcomes of a logistic regression analysis. Prostate 68: 1674–1680.
53. Kumar-Sinha C. Tomlins S. Chinnaiyan A. (2008) Recurrent gene fusions in prostate cancer. Nat Rev Cancer 8: 497–511.
54. Laxman B. Tomlins S. Mehra R. Morris D. Wang L. Helgeson B. (2006) Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 8: 885–888.
55. Le B. Griffin C. Loeb S. Carvalhal G. Kan D. Baumann N. (2010) [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J Urol 183: 1355–1359.
56. Lee W. Morton R. Epstein J. Brooks J. Campbell P. Bova G. (1994) Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A 91: 11733–11737.
57. Lesko L. Atkinson A. (2001) Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol 41: 347–366.
58. Leyten G. Hessels D. Jannink S. Smit F. de Jong H. Cornel E. (2012) Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol: doi:10.1016/j.eururo.2012.11.014 [Epub ahead of print]
59. Lilja H. Christensson A. Dahlén U. Matikainen M. Nilsson O. Pettersson K. (1991) Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 37: 1618–1625.
60. Lilja H. Cronin A. Dahlin A. Manjer J. Nilsson P. Eastham J. (2011) Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer 117: 1210–1219.
61. Loeb S. Roehl K. Antenor J. Catalona W. Suarez B. K. Nadler R. (2006) Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology 67: 316–320.
62. Lowe F. Trauzzi S. (1993) Prostatic acid phosphatase in 1993. Its limited clinical utility. Urol Clin North Am 20: 589–595.
63. Marks L. Fradet Y. Deras I. Blase A. Mathis J. Aubin S. (2007) PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 69: 532–535.
64. McShane L. Altman D. Sauerbrei W. Taube S. Gion M. Clark G.; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23: 9067–9072.
65. Mikolajczyk S. Marker K. Millar L. Kumar A. Saedi M. Payne J. (2001) A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 61: 6958–6963.
66. Mikolajczyk S. Millar L. Wang T. Rittenhouse H. Marks L. Song W. (2000) A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res 60: 756–759.
67. Minner S. Enodien M. Sirma H. Luebke A. Krohn A. Mayer P. (2011) ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res 17: 5878–5888.
68. Moyer V. for the US Preventive Services Task Force. (2012) Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med 157: 120–134.
69. Nakanishi H. Groskopf J. Fritsche H. Bhadkamkar V. Blase A. Kumar S. (2008) PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 179: 1804–1810.
70. Nakayama M. Bennett C. Hicks J. Epstein J. Platz E. Nelson W. (2003) Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am J Pathol 163: 923–933.
71. Nam R. Sugar L. Yang W. Srivastava S. Klotz L. Yang L. (2007a) Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer 97: 1690–1695.
72. Nam R. Toi A. Klotz L. Trachtenberg J. Jewett M. Appu S. (2007b) Assessing individual risk for prostate cancer. J Clin Oncol 25: 3582–3588.
73. Nelson C. La Creis R. Kidd Sauvageot J. Isaacs W. De Marzo A. Groopman J. (2001) Protection against 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine cytotoxicity and DNA adduct formation in human prostate by glutathione S-transferase P1. Cancer Res 61: 103–109.
74. Penney K. Salinas C. Pomerantz M. Schumacher F. Beckwith C. Lee G. (2009) Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. Clin Cancer Res 15: 3223–3230.
75. Pepe M. Feng Z. Janes H. Bossuyt P. Potter J. (2008) Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 100: 1432–1438.
76. Piironen T. Lövgren J. Karp M. Eerola R. Lundwall A. Dowell B. (1996a) Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum. Clin Chem 42: 1034–1041.
77. Piironen T. Pettersson K. Suonpää M. Stenman U. Oesterling J. Lövgren T. (1996b) In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to alpha 1-antichymotrypsin in blood samples. Urology 48(6A Suppl.): 81–87.
78. Pinsky P. Black A. Kramer B. Miller A. Prorok P. Berg C. (2010) Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Clin Trials 7: 303–311.
79. Porten S. Whitson J. Cowan J. Cooperberg M. Shinohara K. Perez N. (2011) Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol 29: 2795–2800.
80. Recker F. Kwiatkowski M. Piironen T. Pettersson K. Lümmen G. Wernli M. (1998) The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma. Cancer 83: 2540–2547.
81. Ross A. Loeb S. Landis P. Partin A. Epstein J. Kettermann A. (2010) Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 28: 2810–2816.
82. Salinas C. Koopmeiners J. Kwon E. FitzGerald L. Lin D. Ostrander E. (2009) Clinical utility of five genetic variants for predicting prostate cancer risk and mortality. Prostate 69: 363–372.
83. Schedlich L. Bennetts B. Morris B. (1987) Primary structure of a human glandular kallikrein gene. DNA 6: 429–437.
84. Schröder F. Hugosson J. Roobol M. Tammela T. Ciatto S. Nelen V. (2012) Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 366: 981–990.
85. Schröder F. Hugosson J. Roobol M. Tammela T. Ciatto S. Nelen V. (2009a) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360: 1320–1328.
86. Schröder F. Roobol M. Andriole G. Fleshner N. (2009b) Defining increased future risk for prostate cancer: evidence from a population based screening cohort. J Urol 181: 69–74.
87. Siegel R. Naishadham D. Jemal A. (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11–30.
88. Sokoll L. Sanda M. Feng Z. Kagan J. Mizrahi I. Broyles D. (2010) A prospective, multicenter, National Cancer Institute early detection research network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev 19: 1193–1200.
89. Sokoll L. Wang Y. Feng Z. Kagan J. Partin A. Sanda M. (2008) [-2]proenzyme prostate specific antigen for prostate cancer detection: a National Cancer Institute early detection research network validation study. J Urol 180: 539–543.
90. Stenman U. Hakama M. Knekt P. Aromaa A. Teppo L. Leinonen J. (1994) Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet 344: 1594–1598.
91. Thompson I. Ankerst D. Chi C. Goodman P. Tangen C. Lucia M. (2006) Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 98: 501–501.
92. Thompson I. Ankerst D. Chi C. Lucia M. Goodman P. Crowley J. (2005) Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 294: 66–70.
93. Thompson I. Pauler D. Goodman P. Tangen C. Lucia M. Parnes H. (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level. N Engl J Med 350: 2239–2246.
94. Tinzl M. Marberger M. Horvath S. Chypre C. (2004) DD3 RNA analysis in urine? A new perspective for detecting prostate cancer. Eur Urol 46: 182–187.
95. Tomlins S. (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644–648.
96. Tosoian J. J. Loeb S. Kettermann A. Landis P. Elliot D. J. Epstein J. I. (2010) Accuracy of PCA3 measurement in predicting short term biopsy progression in an active surveillance program. J Urol, 183 (2), 534–538.
97. van den Bergh R. Roobol M. Wolters T. van Leeuwen P. Schröder F. (2008) The Prostate Cancer Prevention Trial and European Randomized Study of Screening for Prostate Cancer risk calculators indicating a positive prostate biopsy: a comparison. BJU Int 102: 1068–1073.
98. van Gils M. Hessels D. van Hooij O. Jannink S. Peelen W. Hanssen S. (2007) The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res 13: 939–943.
99. Vickers A. Cronin A. Björk T. Manjer J. Nilsson P. Dahlin A. (2010a) Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ 341: c4521.
100. Vickers A. Cronin A. Roobol M. Savage C. Peltola M. Pettersson K. (2010b) Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol 28: 2493–2498.
101. Vickers A. Gupta A. Savage C. Pettersson K. Dahlin A. Bjartell A. (2011) A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening. Cancer Epidemiol Biomarkers Prev 20: 255–261.
102. Walter L. Bertenthal D. Lindquist K. Konety B. (2006) PSA screening among elderly men with limited life expectancies. JAMA 296: 2336–2342.
103. Wang J. Cai Y. Ren C. Ittmann M. (2006) Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 66: 8347–8351.
104. Whitesel J. Donohue R. Mani J. Mohr S. Scanavino D. Augspurger R. (1984) Acid phosphatase: its influence on the management of carcinoma of the prostate. J Urol 131: 70–72.
105. Whitson J. Porten S. Hilton J. Cowan J. Perez N. Cooperberg M. (2011) The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. J Urol 185: 1656–1660.
106. Woodrum D. Brawer M. Partin A. Catalona W. Southwick P. (1998) Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol 159: 5–12.
107. Woodson K. O–Reilly K. Hanson J. Nelson D. Walk E. Tangrea J. (2008) The usefulness of the detection of GSTP1 methylation in urine as a biomarker in the diagnosis of prostate cancer. J Urol 179: 508–512.
108. Wu A. Reese A. Cooperberg M. Sadetsky N. Shinohara K. (2012) Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer. Prostate Cancer Prostatic Dis 15: 100–105.
109. Zheng S. Sun J. Wiklund F. Smith S. Stattin P. Li G. (2008) Cumulative association of five genetic variants with prostate cancer. N Engl J Med 358: 910–919.